Please ensure Javascript is enabled for purposes of website accessibility

Why Eiger BioPharmaceuticals Stock Sank Today

By Keith Speights – Sep 28, 2020 at 3:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported disappointing news from a clinical study targeting COVID-19 outpatients.

What happened

Shares of Eiger BioPharmaceuticals (EIGR 4.85%) were sinking 18.9% lower as of 3:22 p.m. EDT on Monday. The big decline came after the company announced disappointing results from an investigator-sponsored clinical study evaluating Peginterferon Lambda-1a (Lambda) in treating outpatients with mild and uncomplicated COVID-19. 

So what

Stanford University School of Medicine conducted the study of Lambda in treating COVID-19 patients. In the study, Lambda didn't achieve a statistically different duration of viral shedding compared to placebo. This duration was determined by the time to receive two consecutive negative tests for SARS-CoV-2. The experimental drug also didn't reduce the duration of symptom resolution when compared with placebo.

Person in a lab holding a vial next to a microscope

Image source: Getty Images.

This doesn't necessarily mean the end of the road for Lambda as a potential treatment for COVID-19. Colin Hislop, Eiger's senior vice president of clinical and development operations, said in a statement: "We now know that untreated patients with mild COVID-19 clear virus quickly. Published reports have demonstrated evidence of a therapeutic benefit of interferons in hospitalized patients with more advanced COVID-19 disease."

Hislop noted that there are four other ongoing investigator-sponsored studies of Lambda in hospitalized patients with advanced COVID-19. Another investigator-sponsored study is evaluating the experimental drug as prophylaxis for exposed or at-risk patients.

Now what

Eiger has a potential catalyst on the way that could enable the biotech stock to rebound from today's bad news. The U.S. Food and Drug Administration is expected to announce an approval decision for Zokinvy in treating progeria and progeroid laminopathies, rare genetic disorders that cause symptoms of aging at very early ages, by Nov. 20, 2020.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eiger BioPharmaceuticals Stock Quote
Eiger BioPharmaceuticals
$4.54 (4.85%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.